Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC) announced it will release its second quarter 2021 financial results on August 10, 2021, prior to market open. A conference call and webcast are scheduled for 8:00 a.m. ET to discuss the results and recent corporate developments. The company specializes in developing treatments for genetically defined rare diseases. It has advanced losmapimod into Phase 2 clinical trials for facioscapulohumeral dystrophy and FTX-6058 into Phase 1 clinical trials for sickle cell disease and beta-thalassemia.

Positive

• Advanced losmapimod to Phase 2 clinical development.
• FTX-6058 has moved into Phase 1 clinical development.

Negative

• None.

CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second quarter 2021 financial results will be released on Tuesday, August 10, 2021 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Dial-in Number
U.S./Canada Dial-in Number: 800-527-6973
International Dial-in Number: 470-495-9162
Conference ID: 3291056

Replay Dial-in Number: 855-859-2056
Replay International Dial-in Number: 404-537-3406
Conference ID: 3291056

An audio webcast will be accessible through the Investor Relations section of the company’s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.

About Fulcrum Therapeutics 
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.

Please visit www.fulcrumtx.com.

Contact:
Christi Waarich
Director, Investor Relations and
Corporate Communications
617-651-8664
cwaarich@fulcrumtx.com

FAQ

When will Fulcrum Therapeutics release its Q2 2021 financial results?

Fulcrum Therapeutics will release its Q2 2021 financial results on August 10, 2021, before the U.S. financial markets open.

What are the key products being developed by Fulcrum Therapeutics?

Fulcrum Therapeutics is developing losmapimod for facioscapulohumeral dystrophy and FTX-6058 for sickle cell disease and beta-thalassemia.

What time is the conference call for Fulcrum Therapeutics?

The conference call for Fulcrum Therapeutics will occur at 8:00 a.m. ET on August 10, 2021.

How can I access the Fulcrum Therapeutics Q2 2021 financial results webcast?

The webcast can be accessed through the Investor Relations section of Fulcrum Therapeutics' website.